David H. Au

David H. Au

Auto-generated profile, based on publicly available information

David H. Au

Division of Pulmonary, Critical Care, and Sleep Medicine, University of Washington School of Medicine, Seattle, WA 98195-6522

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2012 in Chest
Verified
Journal Article
Closed access
DADavid H. Au
David H. Au
EUEdmunds M. Udris
Edmunds M. Udris
RERuth A. Engelberg
Ruth A. Engelberg
PDPaula H. Diehr
Paula H. Diehr
CBChristopher L. Bryson
Christopher L. Bryson
JCJ. Randall Curtis
J. Randall Curtis

23 January 2007 in Alcohol, Clinical and Experimental Research
Verified
Journal Article
Closed access
PDF file
DADavid H. Au
David H. Au
DKDaniel R. Kivlahan
Daniel R. Kivlahan
CBChris L. Bryson
Chris L. Bryson
DBDavid Blough
David Blough
KBKatharine A. Bradley
Katharine A. Bradley

1 March 2017 in Healthcare
Verified
Journal Article
Closed access
GSGeorge G. Sayre
George G. Sayre
LHLeah M. Haverhals
Leah M. Haverhals
SBSherry Ball
Sherry Ball
LSLauren Stevenson
Lauren Stevenson
CBCatherine Battaglia
Catherine Battaglia
DADavid Au
David Au

11 July 2012 in Journal of General Internal Medicine
Verified
Journal Article
Closed access
PDF file
JHJohn Huetsch
John Huetsch
JUJane E. Uman
Jane E. Uman
EUEdmunds M. Udris
Edmunds M. Udris
DADavid H. Au
David H. Au

1 November 2016 in Annals of the American Thoracic Society
Verified
Journal Article
Closed access
CSChristopher G. Slatore
Christopher G. Slatore
RWRenda Soylemez Wiener
Renda Soylemez Wiener
SGSara E. Golden
Sara E. Golden
DADavid H. Au
David H. Au
LGLinda Ganzini
Linda Ganzini
Rationale: Millions of patients are diagnosed with pulmonary nodules every year. Increased distress may be a common harm, but methods of mitigating this distress are unclear. Objectives: We aimed to determine whether high-quality communication regarding the discovery of a pulmonary nodule is associated with a lower level of patient distress. Methods: We conducted a prospective, repeated-measures cohort study of 121 patients with newly reported, incidentally detected pulmonary nodules. The primary exposure was participant-reported quality of communication regarding the nodule. Secondary exposures included communication measures regarding participants’ values, preferences, and decision making. The main outcome was nodule-related distress measured using the Impact of Event Scale. We used adjusted generalized estimating equations to measure the association between nodule communication quality and at least mild distress. Measurements and Main Results: Most participants (57%) reported at least mild distress at least once. While average distress scores decreased over time, one-fourth still had elevated distress after 2 years of surveillance for a nodule. The average calculated risk of cancer at baseline was 10% (SD, 13%), but 52.4% believed they had a greater than 30% risk of lung cancer at baseline, and this percentage remained fairly constant at all visits. High-quality nodule communication was associated with decreased odds of distress (adjusted odds ratio, 0.42; 95% confidence interval, 0.24–0.73). Lower-quality communication processes regarding participants’ values and preferences were also associated with increased odds of distress, but concordance between the actual and preferred decision-making roles was not. Conclusions: Among patients with incidentally discovered pulmonary nodules, distress is common and persistent for about 25%. Many participants substantially overestimate their risk of lung cancer. Incorporating patients’ values and preferences into communication about a pulmonary nodule and its evaluation may mitigate distress.

3 July 2014 in Allergy, Asthma & Clinical Immunology
Verified
Journal Article
Open access
PDF file
SRSeppo T Rinne
Seppo T Rinne
LFLaura C Feemster
Laura C Feemster
BCBridget F Collins
Bridget F Collins
DADavid H Au
David H Au
MPMark Perkins
Mark Perkins
CLChuan-Fen Liu
Chuan-Fen Liu
Thiazolidinediones are oral diabetes medications that selectively activate peroxisome proliferator-activated receptor gamma and have potent anti-inflammatory properties. While a few studies have found improvements in pulmonary function with exposure to thiazolidinediones, there are no studies of their impact on asthma exacerbations. Our objective was to assess whether exposure to thiazolidinediones was associated with a decreased risk of asthma exacerbation.